Lipids, statins and heart failure: An update

Current Pharmaceutical Design

Volumn 22, Issue 31, 2016, Pages 4796-4806

  Katsiki, Niki ^a   Doumas, Michael ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cardiovascular risk factors; Heart failure; Lipids; Metabolic syndrome; Non alcoholic fatty liver disease; Statins; Trials

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PITAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARRHYTHMOGENESIS; CHRONIC KIDNEY FAILURE; DISEASE PREDISPOSITION; ENDOTHELIAL DYSFUNCTION; EPICARDIAL FAT; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART VENTRICLE REMODELING; HUMAN; HYPERURICEMIA; INFLAMMATION; LIPID METABOLISM; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTE DYSFUNCTION; METABOLISM;

HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; LIPIDS;

EID: 85010696603     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160701073452     Document Type: Review

References (261)

1. Strandberg TE. Lipid-lowering drugs and heart failure: where do we go after the statin trials? Curr Opin Cardiol 2010; 25: 385-93.
2. Alba AC, Delgado DH. Optimal medical treatment of cardiovascular risk factors: can we prevent the development of heart failure? Expert Rev Cardiovasc Ther 2009; 7: 147-57.
3. Gardner JD, Mouton AJ. Alcohol effects on cardiac function. Compr Physiol 2015; 5: 791-802.
4. Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond) 2016; 130: 57-77.
5. Glezeva N, Horgan S, Baugh JA. Monocyte and macrophage subsets along the continuum to heart failure: Misguided heroes or targetable villains? J Mol Cell Cardiol 2015; 89: 136-45.
6. Münzel T, Gori T, Keaney JF Jr., Maack C, Daiber A. Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. Eur Heart J 2015; 36: 2555-64.
7. Shantsila E, Wrigley BJ, Blann AD, Gill PS, Lip GY. A contemporary view on endothelial function in heart failure. Eur J Heart Fail 2012; 14: 873-81.
8. Brower GL, Gardner JD, Forman MF, et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 2006; 30: 604-10.
9. Yang J, Xu WW, Hu SJ. Heart failure: advanced development in genetics andepigenetics. Biomed Res Int 2015; 2015: 352734.
10. Palomer X, Barroso E, Zarei M, Botteri G, Vázquez-Carrera M. PPARβ/δ and lipid metabolism in the heart. Biochim Biophys Acta 2016; 1860(10): 1569-78.
11. Bang C, Antoniades C, Antonopoulos AS, et al. Intercellularcommunication lessons in heart failure. Eur J Heart Fail 2015; 17: 1091-103.
12. Bedi KC Jr., Snyder NW, Brandimarto J, et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 2016; 133(8): 706-16.
13. Ardehali H, Sabbah HN, Burke MA, et al. Targeting myocardial substratemetabolism in heart failure: potential for new therapies. Eur J Heart Fail 2012; 14: 120-9.
14. Vaduganathan M, Greene SJ, Ambrosy AP, Gheorghiade M. Lipids, statins, and Clinical outcomes in heart failure: rethinking the data. Heart Fail Rev 2014; 19: 695-8.
15. Horwich TB, Hernandez AF, Dai D, Yancy CW, Fonarow GC. Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. Am Heart J 2008; 156: 1170-6.
16. Chen Y, He XM, Meng H, et al. Relationship between lipids levels and right ventricular volume overload in congestive heart failure. J Geriatr Cardiol 2014; 11: 192-9.
17. Karadag MK, Akbulut M. Low HDL levels as the most common metabolic syndrome risk factor in heart failure. Int Heart J 2009; 50: 571-80.
18. Mehra MR, Uber PA, Lavie CJ, Milani RV, Park MH, Ventura HO. High-density lipoprotein cholesterol levels and prognosis in advanced heart failure. J Heart Lung Transplant 2009; 28: 876-80.
19. Al Qahtani M, Al Backer T, Al Anazi T, et al. Impact of lipid disorders on mortality among Saudi patients with heart failure. J Saudi Heart Assoc 2015; 27: 91-5.
20. Van Linthout S, Frias M, Singh N, De Geest B. Therapeutic potential of HDL in cardioprotection and tissue repair. Handb Exp Pharmacol 2015; 224: 527-65.
21. Gordts SC, Singh N, Muthuramu I, De Geest B. Pleiotropic effects of HDL: towards new therapeutic areas for HDL-targeted interventions. Curr Mol Med 2014; 14: 481-503.
22. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Highdensity lipoprotein, vascular risk, cancer and infection: a case of quantity and quality? Curr Med Chem 2014; 21: 2917-26.
23. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012; 51: 314-24.
24. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Should raising high-density lipoprotein cholesterol be a matter of debate? J Cardiovasc Med (Hagerstown) 2012; 13: 254-9.
25. Zanoni P, Khetarpal SA, Larach DB, et al. CHD Exome+ Consortium; CARDIoGRAM Exome Consortium; Global Lipids Genetics Consortium. Rare variant in scavenger receptor BI raises HDL cho lesterol and increases risk of coronary heart disease. Science 2016; 351: 1166-71.
26. Patel PJ, Khera AV, Wilensky RL, Rader DJ. Anti-oxidative and cholesterolefflux capacities of high-density lipoprotein are reduced in ischaemiccardiomyopathy. Eur J Heart Fail 2013; 15: 1215-9.
27. Greene SJ, Vaduganathan M, Lupi L, et al. EVEREST Trial Investigators. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol 2013; 111: 574-81.
28. Kozdag G, Ertas G, Emre E, et al. Low serum triglyceride levels as predictors of cardiac death in heart failure patients. Tex Heart Inst J 2013; 40: 521-8.
29. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003; 42: 1933-40.
30. Afsarmanesh N, Horwich TB, Fonarow GC. Total cholesterol levels and mortality risk in nonischemic systolic heart failure. Am Heart J 2006; 152: 1077-83.
31. Silva S, Lourenço P, Paulo C, et al. Statin-induced low cholesterol is notassociated with poor outcome in chronic heart failure. J Cardiovasc Pharmacol Ther 2012; 17: 284-90.
32. Nakagomi A, Seino Y, Noma S, et al. Relationships between the serum cholesterol levels, production ofmonocyte proinflammatory cytokines and long-term prognosis in patients withchronic heart failure. Intern Med 2014; 53: 2415-24.
33. Kahn MR, Kosmas CE, Wagman G, et al. Low-density lipoprotein levels in patients with acute heart failure. Congest Heart Fail 2013; 19: 85-91.
34. Horwich T. Low-density lipoprotein in the setting of congestive heart failure: is lower really better? Curr Atheroscler Rep 2009; 11: 343-9.
35. Freitas HF, Barbosa EA, Rosa FH, Lima AC, Mansur AJ. Association of HDL cholesterol and triglycerides with mortality in patients with heart failure. Braz J Med Biol Res 2009; 42: 420-5.
36. Zhao G, Huang L, Song M, Song Y. Baseline serum uric acid level as a predictorof cardiovascular disease related mortality and allcause mortality: ameta-analysis of prospective studies. Atherosclerosis 2013; 231: 61-8.
37. Borghi C, Verardi FM, Pareo I, Bentivenga C, Cicero AF. Hyperuricemia andcardiovascular disease risk. Expert Rev Cardiovasc Ther 2014; 12: 1219-25.
38. Katsiki N, Karagiannis A, Athyros VG, Mikhailidis DP. Hyperuricaemia: more than just a cause of gout? J Cardiovasc Med (Hagerstown) 2013; 14: 397-402.
39. Viazzi F, Leoncini G, Ratto E, Pontremoli R. Hyperuricemia and renal risk. High Blood Press Cardiovasc Prev 2014; 21: 189-94.
40. Rizzo M, Obradovic M, Labudovic-Borovic M, et al. Uric acid metabolism in pre-hypertension and themetabolic syndrome. Curr Vasc Pharmacol 2014; 12: 572-85.
41. Papanas N, Demetriou M, Katsiki N, et al. Increased serum levels of uric acid are associated with sudomotor dysfunction in subjects with type 2 diabetes mellitus. Exp Diabetes Res 2011; 2011: 346051.
42. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia andnon-alcoholic fatty liver disease (NAFLD): a relationship with implications forvascular risk? Curr Vasc Pharmacol 2011; 9: 698-705.
43. Katsiki N, Papanas N, Fonseca VA, Maltezos E, Mikhailidis DP. Uric acid and diabetes: Is there a link? Curr Pharm Des 2013; 19: 4930-7.
44. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. Curr Vasc Pharmacol 2014; 12: 627-41.
45. Athyros VG, Mikhailidis DP. Uric acid, chronic kidney disease and type 2diabetes: a cluster of vascular risk factors. J Diabetes Complications 2014; 28: 122-3.
46. Gluba A, Bielecka-Dabrowa A, Mikhailidis DP, et al. An update on biomarkers of heart failure in hypertensive patients. J Hypertens 2012; 30: 1681-9.
47. Doehner W, Jankowska EA, Springer J, Lainscak M, Anker SD. Uric acid and xanthine oxidase in heart failure-Emerging data and therapeutic implications. Int J Cardiol 2016; 213: 15-9.
48. Gotsman I, Keren A, Lotan C, Zwas DR. Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. J Card Fail 2012; 18: 694-701.
49. von Lueder TG, Girerd N, Atar D, et al. High-Risk Myocardial Infarction DatabaseInitiative Investigators. Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative. Eur J Heart Fail 2015; 17: 1144-51.
50. Borghi C, Cosentino ER, Rinaldi ER, Cicero AF. Uricaemia and ejection fraction in elderly heart failure outpatients. Eur J Clin Invest 2014; 44: 573-8.
51. Shimizu T, Yoshihisa A, Kanno Y, et al. Relationship of hyperuricemia with mortality in heart failure patients with preserved ejectionfraction. Am J Physiol Heart Circ Physiol 2015; 309: H1123-9.
52. Vaduganathan M, Greene SJ, Ambrosy AP, et al. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reducedejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am J Cardiol 2014; 114: 1713-21.
53. Huang H, Huang B, Li Y, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail 2014; 16: 15-24.
54. Tamariz L, Hernandez F, Bush A, Palacio A, Hare JM. Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm 2014; 11: 1102-8.
55. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Metabolic syndrome and non-cardiac vascular diseases: an update from human studies. Curr Pharm Des 2014; 20: 4944-52.
56. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006; 55: 1293-301.
57. Kostapanos MS, Florentin M, Elisaf MS, Mikhailidis DP. Hemostatic factors and the metabolic syndrome. Curr Vasc Pharmacol 2013; 11: 880-905.
58. Roberts AW, Clark AL, Witte KK. Review article: Left ventricular dysfunction and heart failure in metabolic syndrome and diabetes without overt coronary artery disease--do we need to screen our patients? Diab Vasc Dis Res 2009; 6: 153-63.
59. Perrone-Filardi P, Paolillo S, Costanzo P, Savarese G, Trimarco B, Bonow RO. The role of metabolic syndrome in heart failure. Eur Heart J 2015; 36: 2630-4.
60. Gaddam KK, Ventura HO, Lavie CJ. Metabolic syndrome and heart failure—therisk, paradox, and treatment. Curr Hypertens Rep 2011; 13: 142-8.
61. La Carrubba S, Antonini-Canterin F, Fabiani I, et al. Prevalence and prognostic impact of metabolic syndrome in asymptomatic (stage A and B heart failure) patients. Metab Syndr Relat Disord 2016; 14(3): 187-94.
62. Tadaki S, Sakata Y, Miura Y, et al. Prognostic impacts of metabolic syndrome in patients with chronicheart failure-a multicenter prospective cohort study. Circ J 2016; 80(3): 677-88.
63. Azzam H, Malnick S. Non-alcoholic fatty liver disease-the heart of the matter. World J Hepatol 2015; 7: 1369-76.
64. Hyogo H, Chayama K, Yamagishi S. Nonalcoholic fatty liver disease andcardiovascular disease. Curr Pharm Des 2014; 20: 2403-11.
65. Katsiki N, Athyros VG, Karagiannis A, Wierzbicki AS, Mikhailidis DP. Should we expand the concept of coronary heart disease equivalents? Curr Opin Cardiol 2014; 29: 389-95.
66. Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J Gastroenterol 2014; 20: 13306-24.
67. Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol 2014; 34: 1155-61.
68. Perazzo H, Poynard T, Dufour JF. The interactions of nonalcoholic fatty liver disease and cardiovascular diseases. Clin Liver Dis 2014; 18: 233-48.
69. Mantovani A, Ballestri S, Lonardo A, Targher G. Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease. Dig Dis Sci 2016; 61(5): 1246-67.
70. Käräjämäki AJ, Pätsi OP, Savolainen M, Kesäniemi YA, Huikuri H, Ukkola O. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation inmiddle-aged population (OPERA Study). PLoS One 2015; 10: e0142937
71. Targher G, Valbusa F, Bonapace S, et al. Non-alcoholic fatty liver disease isassociated with an increased incidence of atrial fibrillation in patients withtype 2 diabetes. PLoS One 2013; 8: e57183.
72. Petta S, Argano C, Colomba D, et al. Epicardial fat, cardiac geometry andcardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol 2015; 62: 928-33.
73. Mantovani A, Zoppini G, Targher G, Golia G, Bonora E. Nonalcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. J Endocrinol Invest 2012; 35: 215-8.
74. Fallo F, Dalla Pozza A, Sonino N, et al. Non-alcoholic fatty liver disease is associated with left ventriculardiastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 2009; 19: 646-53.
75. Hallsworth K, Hollingsworth KG, Thoma C, et al. Cardiac structure and function are altered inadults with non-alcoholic fatty liver disease. J Hepatol 2013; 58: 757-62.
76. Singh GK, Vitola BE, Holland MR, et al. Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease. J Pediatr 2013; 162: 1160-8.
77. Pacifico L, Chiesa C, Anania C, et al. Nonalcoholic fatty liver disease and the heart in children and adolescents. World J Gastroenterol 2014; 20: 9055-71.
78. Fintini D, Chinali M, Cafiero G, et al. Early left ventricular abnormality/ dysfunction in obese children affected by NAFLD. Nutr Metab Cardiovasc Dis 2014; 24: 72-4.
79. Valbusa F, Bonapace S, Grillo C, et al. Nonalcoholic fatty liver disease is associated with higher 1-year all-cause rehospitalization rates in patients admitted for acute heart failure. Medicine (Baltimore) 2016; 95: e2760.
80. Duman DG, Biçakci E, Çelikel ÇA, Akbal C. Nonalcoholic Fatty Liver Disease is Associated With Erectile Dysfunction: A Prospective Pilot Study. J Sex Med 2016; 13(3): 383-8.
81. Chou TC, Liang WM, Wang CB, Wu TN, Hang LW. Obstructive sleep apnea is associated with liver disease: a population-based cohort study. Sleep Med 2015; 16: 955-60.
82. Arias-Loste MT, Fábrega E, López-Hoyos M, Crespo J. The crosstalk between hypoxia and innate immunity in the development of obesity-related nonalcoholic fatty liver disease. Biomed Res Int 2015; 2015: 319745.
83. Katsiki N, Wierzbicki AS, Mikhailidis DP. Erectile dysfunction and coronary heart disease. Curr Opin Cardiol 2015; 30: 416-21.
84. Rodrigues FL, Fais RS, Tostes RC, Carneiro FS. There is a link betweenerectile dysfunction and heart failure: it could be inflammation. Curr DrugTargets 2015; 16: 442-50.
85. Vrentzos GE, Paraskevas KI, Mikhailidis DP. Dyslipidemia as a risk factor for erectile dysfunction. Curr Med Chem 2007; 14: 1765-70.
86. Kostis JB, Dobrzynski JM. The effect of statins on erectile dysfunction: a meta-analysis of randomized trials. J Sex Med 2014; 11: 1626-35.
87. Kostapanos MS, Mikhailidis DP, Elisaf MS, Steiropoulos P, Papanas N. Obstructive sleep apnoea syndrome and cardiovascular risk. Arch Med Sci 2012; 8: 1115-6.
88. Lyons OD, Bradley TD. Heart Failure and Sleep Apnea. Can J Cardiol 2015; 31: 898-908.
89. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. The role of statins in the treatment of type 2 diabetes mellitus: an update. Curr Pharm Des 2014; 20: 3665-74.
90. Katsiki N, Mikhailidis DP, Wierzbicki AS. Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol 2013; 28: 458-63.
91. Karayannis G, Giamouzis G, Tziolas N, et al. Association between epicardial fat thickness and weight homeostasis hormones in patients with noncachectic heart failure. Angiology 2013; 64: 173-80.
92. Fontes-Carvalho R, Fontes-Oliveira M, Sampaio F, et al. Influence of epicardialand visceral fat on left ventricular diastolic and systolic functions in patientsafter myocardial infarction. Am J Cardiol 2014; 114: 1663-9.
93. Tabakci MM, Durmuş Hİ, Avci A, et al. Relation of epicardial fat thickness tothe severity of heart failure in patients with nonischemic dilatedcardiomyopathy. Echocardiography 2015; 32: 740-8.
94. Lin HH, Lee JK, Yang CY, Lien YC, Huang JW, Wu CK. Accumulation of epicardial fat rather than visceral fat is an independent risk factor for left ventriculardiastolic dysfunction in patients undergoing peritoneal dialysis. Cardiovasc Diabetol 2013; 12: 127.
95. Iacobellis G, Zaki MC, Garcia D, Willens HJ. Epicardial fat in atrialfibrillation and heart failure. Horm Metab Res 2014; 46: 587-90.
96. Whayne TF Jr. Epicardial fat thickness in heart failure and other clinical conditions. Angiology 2013; 64: 169-72.
97. Katsiki N, Athyros VG, Mikhailidis DP. Abnormal Peri-organ or Intra-organ Fat (APIFat) deposition: an underestimated predictor of vascular risk? Curr Vasc Pharmacol 2016; [Epub ahead of print].
98. Watanabe K, Kishino T, Sano J, et al. Relationship between epicardial adipose tissue thickness and early impairment of left ventricular systolic function in patients with preserved ejection fraction. Heart Vessels 2016; 31(6): 1010-5.
99. Koumaras C, Katsiki N, Athyros VG, Karagiannis A. Metabolic syndrome andarterial stiffness: the past, the present and the future. J Cardiovasc Med(Hagerstown) 2013; 14: 687-9.
100. Katsiki N, Koumaras C, Athyros VG, Karagiannis A. Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk. Angiology 2012; 63: 9-11.
101. Kim BJ, Kim BS, Kang JH. Echocardiographic epicardial fat thickness is associated with arterial stiffness. Int J Cardiol 2013; 167: 2234-8.
102. Korkmaz L, Cirakoglu OF, Ağaç MT, et al. Relation of epicardial adipose tissue with arterial compliance andstiffness in patients with hypertension. Angiology 2014; 65: 691-5.
103. Sunbul M, Agirbasli M, Durmus E, et al. Arterial stiffness in patients with non-alcoholic fatty liver disease isrelated to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis 2014; 237: 490-3.
104. Taal MW. Arterial stiffness in chronic kidney disease: an update. Curr Opin Nephrol Hypertens 2014; 23: 169-73.
105. Townsend RR, Tomiyama H. Arterial stiffness, kidney function, and chronic kidney disease progression. Pulse (Basel) 2013; 1: 123-30.
106. Li N, Zhang GW, Zhang JR, et al. Non-alcoholic fattyliver disease is associated with progression of arterial stiffness. Nutr Metab Cardiovasc Dis 2015; 25: 218-23.
107. Tsao CW, Lyass A, Larson MG, et al. Relation of central arterial stiffness to incident heart failure in the community. J Am Heart Assoc 2015; 4(11).
108. Chow B, Rabkin SW. The relationship between arterial stiffness and heartfailure with preserved ejection fraction: a systemic metaanalysis. Heart Fail Rev 2015; 20: 291-303.
109. Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol 2012; 60: 1455-69.
110. Duprez DA. Arterial stiffness/elasticity in the contribution to progression ofheart failure. Heart Fail Clin 2012; 8: 135-41.
111. Demir S, Akpınar O, Akkus O, et al. The prognostic value of arterial stiffness in systolic heart failure. Cardiol J 2013; 20: 665-71.
112. Cremer A, Lainé M, Papaioannou G, Yeim S, Gosse P. Increased arterial stiffness is an independent predictor of atrial fibrillation in hypertensive patients. J Hypertens 2015; 33: 2150-5.
113. Lau DH, Middeldorp ME, Brooks AG, et al. Aortic stiffness in lone atrial fibrillation: a novel risk factor for arrhythmia recurrence. PLoS One 2013; 8: e76776.
114. Larstorp AC, Ariansen I, Gjesdal K, et al. Association of pulse pressure with new-onsetatrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. Hypertension 2012; 60: 347-53.
115. Fabbian F, Pala M, De Giorgi A, et al. Clinical features of cardiorenal syndrome in a cohort ofconsecutive patients admitted to an internal medicine ward. Open Cardiovasc Med J 2011; 5: 220-5.
116. Latini R, Aleksova A, Masson S. Novel biomarkers and therapies in cardiorenalsyndrome. Curr Opin Pharmacol 2016; 27: 56-61.
117. Waldum-Grevbo B. What physicians need to know about renal function inoutpatients with heart failure. Cardiology 2015; 131: 130-8.
118. Rajapakse NW, Nanayakkara S, Kaye DM. Pathogenesis and treatment of thecardiorenal syndrome: Implications of L-arginine-nitric oxide pathway impairment. Pharmacol Ther 2015; 154: 1-12.
119. Di Lullo L, Gorini A, Russo D, Santoboni A, Ronco C. Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment. Cardiorenal Med 2015; 5: 254-66.
120. Nerpin E, Ingelsson E, Risérus U, et al. The association between glomerular filtration rate and left ventricular function in two independent community-based cohorts of elderly. Nephrol Dial Transplant 2014; 29: 2069-74.
121. Briasoulis A, Androulakis E, Christophides T, Tousoulis D. The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Fail Rev 2016; 21: 169-76.
122. Brunetti ND, Maulucci G, Casavecchia GP, et al. Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison atorvastatin20 mg vs. rosuvastatin 10 mg. J Interv Cardiol 2007; 20: 481-7.
123. Agouridis AP, Elisaf MS, Nair DR, Mikhailidis DP. All for Statins and Statins for All; An Update. Curr Pharm Des 2015; 22: 18-27.
124. Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins asanti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012; 18: 1519-30.
125. Oi S, Haneda T, Osaki J, et al. Lovastatin prevents angiotensin IIinduced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 1999; 376: 139-48.
126. Bielecka-Dabrowa A, Mikhailidis DP, Hannam S, Aronow WS, Rysz J, Banach M. Statins and dilated cardiomyopathy: do we have enough data? Expert Opin Investig Drugs 2011; 20: 315-23.
127. Sodha NR, Sellke FW. The effect of statins on perioperative inflammation incardiac and thoracic surgery. J Thorac Cardiovasc Surg 2015; 149: 1495-501.
128. Owens CD. Statins and other agents for vascular inflammation. J Vasc Surg 2012; 56: 1799-806.
129. Yousuf O, Mohanty BD, Martin SS, et al. High-sensitivity Creactive protein and cardiovascular disease: aresolute belief or an elusive link? J Am Coll Cardiol 2013; 62: 397-408.
130. Bielecka-Dabrowa A, Mikhailidis DP, Rizzo M, von Haehling S, Rysz J, Banach M. The influence of atorvastatin on parameters of inflammation left ventricularfunction, hospitalizations and mortality in patients with dilatedcardiomyopathy--5-year follow-up. Lipids Health Dis 2013; 12: 47.
131. Deedwania PC, Stone PH, Fayyad RS, Laskey RE, Wilson DJ. Improvement in renal function and reduction in serum uric acid with intensive statin therapy in older patients: a post Hoc analysis of the SAGE trial. Drugs Aging 2015; 32: 1055-65.
132. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins--clinical evidence. Curr Pharm Des 2009; 15: 479-89.
133. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascularevents in patients with coronary heart disease and metabolic syndrome: a subgroupanalysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: 118-27.
134. Athyros VG, Karagiannis A, Ganotakis ES, et al. Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome inpatients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011; 27: 1659-68.
135. Stypmann J, Schubert A, Welp H, et al. Atorvastatin therapy is associated with reduced levels of N-terminal prohormone brain natriuretic peptide and improved cardiac function in patients with heart failure. Clin Cardiol 2008; 31: 478-81.
136. Sahebkar A, Kotani K, Serban C, et al. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. Atherosclerosis 2015; 241: 433-42.
137. Sahebkar A, Serban MC, Mikhailidis DP, et al. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group.Head-tohead comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. Pharmacol Res 2016; 103: 236-52.
138. Undas A, Brummel-Ziedins KE, Mann KG. Anticoagulant effects of statins andtheir clinical implications. Thromb Haemost 2014; 111: 392-400.
139. Violi F, Calvieri C, Ferro D, Pignatelli P. Statins as antithrombotic drugs. Circulation 2013; 127: 251-7.
140. Kramkowski K, Leszczynska A, Buczko W. Pharmacological modulation of fibrinolytic response-In vivo and in vitro studies. Pharmacol Rep 2015; 67: 695-703.
141. Sahebkar A, Serban C, Mikhailidis DP, et al. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost 2015; 114: 546-57.
142. Satoh M, Takahashi Y, Tabuchi T, et al. Cellular and molecular mechanisms of statins: an update on pleiotropic effects. Clin Sci (Lond) 2015; 129: 93-105.
143. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease. Curr Pharm Des 2014; 20: 6299-305.
144. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention. Curr Med Res Opin 2015; 31: 191-5.
145. Li XD, Yang YJ, Hao YC, et al. Effect of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention: a meta analysis. Chin Med J (Engl) 2013; 126: 1755-60.
146. Lyu T, Zhao Y, Zhang T, et al. Effect of statin pretreatment on myocardial perfusion in patients undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis. Clin Cardiol 2013; 36: E17-24.
147. Chopra V, Wesorick DH, Sussman JB, et al. Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: a systematic review and meta-analysis. Arch Surg 2012; 147: 181-9.
148. Luo J, Xu L, Yu T, Li J. Effect of statins therapy prior to percutaneouscoronary intervention. J Interv Cardiol 2012; 25: 156-62.
149. Variya BC, Patel SS, Trivedi JI, Gandhi HP, Rathod SP. Comparative evaluation of HMG CoA reductase inhibitors in experimentally-induced myocardial necrosis: Biochemical, morphological and histological studies. Eur J Pharmacol 2015; 764: 283-91.
150. Athyros VG, Tziomalos K, Florentin M, Karagiannis A, Mikhailidis DP. Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect? Curr Med Res Opin 2010; 26: 839-42.
151. Kumar A, Cannon CP. The role of statins in the prevention of heart failure after acute coronary syndrome. Heart Fail Clin 2008; 4: 129-39.
152. Wick G, Jakic B, Buszko M, Wick MC, Grundtman C. The role of heat shockproteins in atherosclerosis. Nat Rev Cardiol 2014; 11: 516-29.
153. Rizzo M, Macario AJ, de Macario EC, et al. Heat shock protein-60 and risk for cardiovascular disease. Curr Pharm Des 2011; 17): 3662-8.
154. Bielecka-Dabrowa A, Barylski M, Mikhailidis DP, Rysz J, Banach M. HSP 70 andatherosclerosis--protector or activator? Expert Opin Ther Targets 2009; 13: 307-17.
155. Willis MS, Patterson C. Hold me tight: Role of the heat shock protein family of chaperones in cardiac disease. Circulation 2010; 122: 1740-51.
156. Niizeki T, Takeishi Y, Watanabe T, et al. Relation of serum heat shock protein 60 level to severity and prognosis in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2008; 102: 606-10.
157. Guisasola MC, Dulín E, Almendral J, García-Barreno P. Reduction of heat shock protein antibody levels by statin therapy. Lipids 2009; 44: 317-24.
158. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improvement of left ventricular remodelling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001; 104: 982-7.
159. Martin J, Denver R, Bailey M, Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clin Exp Pharmacol Physiol 2005; 32: 697-701.
160. Grip O, Janciauskiene S, Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. Eur J Pharmacol 2000; 410: 83-92.
161. Laufs U, Custodis F, Böhm M. HMG-CoA reductase inhibitors in chronic heartfailure: potential mechanisms of benefit and risk. Drugs 2006; 66: 145-54.
162. Holm T, Andreassen AK, Ueland T, et al. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am J Cardiol 2001; 87: 815-8.
163. Simko F. Statins: a perspective for left ventricular hypertrophy treatment. Eur J Clin Invest 2007; 37: 681-91.
164. Correale M, Abruzzese S, Greco CA, Concilio M, Biase MD, Brunetti ND. Pleiotropic effects of statin in therapy in heart failure: a review. Curr Vasc Pharmacol 2014; 12: 873-84.
165. Watson G, Oliver E, Zhao L, Wilkins MR. Pulmonary hypertension: old targets revisited (statins, PPARs, beta-blockers). Handb Exp Pharmacol 2013; 218: 531-48.
166. Katsiki N, Wierzbicki AS, Mikhailidis DP. Pulmonary arterial hypertension and statins: an update. Curr Opin Cardiol 2011; 26: 322-6.
167. Zagar TM, Cardinale DM, Marks LB. Breast cancer therapyassociated cardiovascular disease. Nat Rev Clin Oncol 2016; 13(3): 172-84.
168. Salvatorelli E, Menna P, Cantalupo E, et al. The concomitant management of cancer therapy and cardiac therapy. Biochim Biophys Acta 2015; 1848: 2727-37.
169. Truong J, Yan AT, Cramarossa G, Chan KK. Chemotherapyinduced cardiotoxicity: detection, prevention, and management. Can J Cardiol 2014; 30: 869-78.
170. Vasiliadis I, Kolovou G, Mikhailidis DP. Cardiotoxicity and cancer therapy. Angiology 2014; 65: 369-71.
171. Chotenimitkhun R, D’Agostino R Jr., Lawrence JA, et al. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. Can J Cardiol 2015; 31: 302-7.
172. Floras J. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol. 1993; 4: 72A-84A.
173. Pehlivanidis AN, Athyros VG, Demitriadis DS, Papageorgiou AA, Bouloukos VJ, Kontopoulos AG. Heart rate variability after longterm treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001; 151: 463-9.
174. Pliquett R, Cornish K, Zucker I. Statins: the effects on sympathetic nerve activity in heart failure. J Card Fail 2001; 7: 16-26.
175. Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003; 107: 2493-8.
176. Lipinski MJ, Abbate A, Fuster V, Vetrovec GW. Drug insight: statins fornonischemic heart failure--evidence and potential mechanisms. Nat Clin Pract Cardiovasc Med 2007; 4: 196-205.
177. Millar PJ, Floras JS. Statins and the autonomic nervous system. Clin Sci (Lond) 2014; 126: 401-15.
178. Kostapanos MS, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS. Do statins have an antiarrhythmic activity? Cardiovasc Res 2007; 75: 10-20.
179. Cohn JN, Johnson GC, Shabetai R. Mechanistic data from the VA Cooperative studies: ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993; 86: VI5-16.
180. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications forstatins? Med Sci Monit 2009; 15: MS1-MS5.
181. Beri A, Contractor T, Khasnis A, Thakur R. Statins and the reduction of suddencardiac death: antiarrhythmic or anti-ischemic effect? Am J Cardiovasc Drugs 2010; 10: 155-64.
182. Das MK, Zipes DP. Antiarrhythmic and nonantiarrhythmic drugs for suddencardiac death prevention. J Cardiovasc Pharmacol 2010; 55: 438-49.
183. Zhou X, Du JL, Yuan J, Chen YQ. Statin therapy is beneficial for the prevention of atrial fibrillation in patients with coronary artery disease: a meta-analysis. Eur J Pharmacol 2013; 707: 104-11.
184. Goh SL, Yap KH, Chua KC, Chao VT. Does preoperative statin therapy prevent postoperative atrial fibrillation in patients undergoing cardiac surgery? Interact Cardiovasc Thorac Surg 2015; 20: 422-8.
185. Zheng H, Xue S, Hu ZL, Shan JG, Yang WG. The use of statins to preven tpostoperative atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 12 studies. J Cardiovasc Pharmacol 2014; 64: 285-92.
186. Cho KI, Kim BJ, Cha TJ, Heo JH, Kim HS, Lee JW. Impact of duration and dosage of statin treatment and epicardial fat thickness on the recurrence of atrial fibrillation after electrical cardioversion. Heart Vessels 2015; 30: 490-7.
187. Rahimi K, Majoni W, Merhi A, Emberson J. Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials. Eur Heart J 2012; 33: 1571-81.
188. Iacobellis G. Epicardial fat: a new cardiovascular therapeutic target. Curr Opin Pharmacol 2016; 27: 13-18.
189. Park JH, Park YS, Kim YJ, et al. Effects of statins on the epicardial fat thickness in patients with coronary artery stenosis underwent percutaneous coronary intervention: comparison of atorvastatin with simvastatin/ezetimibe. J Cardiovasc Ultrasound 2010; 18: 121-6.
190. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets 2007; 11: 1143-60.
191. Papademetriou V, Katsiki N, Doumas M, Faselis C. Halting arterial aging inpatients with cardiovascular disease: hypolipidemic and antihypertensive therapy. Curr Pharm Des 2014; 20: 6339-49.
192. Bostan C, Yildiz A, Ozkan AA, Uzunhasan I, Kaya A, Yigit Z. Beneficial effectsof rosuvastatin treatment in patients with metabolic syndrome. Angiology 2015; 66: 122-7.
193. Matikainen N, Taskinen MR. Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes. Curr Cardiol Rep 2012; 14: 721-31.
194. Gouni-Berthold I, Berthold HK. Pharmacologic therapy for cardiovascular riskr eduction in patients with the metabolic syndrome. Curr Pharm Des 2014; 20: 5025-38.
195. Wang Y, Yu Q, Chen Y, Cao F. Pathophysiology and therapeutics of cardiovascular disease in metabolic syndrome. Curr Pharm Des 2013; 19: 4799-805.
196. Rubio-Ruiz ME, El Hafidi M, Pérez-Torres I, Baños G, Guarner V. Medicinal agents and metabolic syndrome. Curr Med Chem 2013; 20: 2626-40.
197. Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinicalmanifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21: 6820-34.
198. Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico F. The efficacyand safety of statins for the treatment of non-alcoholic fatty liver disease. DigLiver Dis 2015; 47: 4-11.
199. Dongiovanni P, Petta S, Mannisto V, et al. Statin use and nonalcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63(3): 705-12.
200. Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of nonalcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21: 7860-8.
201. Kargiotis K, Katsiki N, Athyros VG, et al. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report. Curr Vasc Pharmacol 2014; 12: 505-11.
202. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Are statins ’IDEAL’ for non-alcoholic fatty liver disease? Curr Med Res Opin 2014; 30: 229-31.
203. Del Ben M, Polimeni L, Baratta F, Pastori D, Loffredo L, Angelico F. Modernapproach to the clinical management of non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 8341-50.
204. Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liverdisease. World J Gastroenterol 2014; 20: 1712-23.
205. Athyros VG, Tziomalos K, Daskalopoulos GN, Karagiannis A, Mikhailidis DP. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med 2011; 43: 167-71.
206. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Statins and nonalcoholicfatty liver disease: a bright future? Expert Opin Investig Drugs 2013; 22: 1089-93.
207. Athyros VG, Tziomalos K, Gossios TD, et al. GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-22.
208. Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168: 3846-52.
209. Takagi H, Umemoto T. Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials. Int J Cardiol 2012; 157: 255-7.
210. Matsushita K, Ballew SH, Coresh J. Influence of chronic kidney disease on cardiac structure and function. Curr Hypertens Rep 2015; 17: 581.
211. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Contrastinduced nephropathy: an "all or none" phenomenon? Angiology 2015; 66: 508-13.
212. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Statins can improveproteinuria and glomerular filtration rate loss in chronic kidney diseasepatients, further reducing cardiovascular risk. Fact or fiction? Expert Opin Pharmacother 2015; 16: 1449-61.
213. Ball T, McCullough PA. Statins for the prevention of contrastinduced acutekidney injury. Nephron Clin Pract 2014; 127: 165-71.
214. Geng Q, Ren J, Song J, Li S, Chen H. Meta-analysis of the effect of statins onrenal function. Am J Cardiol 2014; 114: 562-70.
215. Nikolic D, Banach M, Nikfar S, et al. Lipid and Blood Pressure-Meta-Analysis Collaboration Group. A meta-analysis of the role of statins onrenal outcomes in patients with chronic kidney disease. Is the duration oftherapy important? Int J Cardiol 2013; 168: 5437-47.
216. Zhang Z, Wu P, Zhang J, Wang S, Zhang G. The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis. Pharmacol Res 2016; 105: 74-83.
217. Athyros VG, Mitsiou EK, Tziomalos K, Karagiannis A, Mikhailidis DP. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across differentstages of diabetic nephropathy. Expert Opin Pharmacother 2010; 11: 723-30.
218. Athyros VG, Katsiki N, Tziomalos K, Karagiannis A. Preventing cardio-renal syndrome rather than treating it: could statins play a role? Open Cardiovasc Med J 2011; 5: 226-30.
219. Milionis HJ, Liberopoulos EN, Elisaf MS, Mikhailidis DP. Analysis of antihypertensive effects of statins. Curr Hypertens Rep 2007; 9: 175-83.
220. Kostapanos MS, Milionis HJ, Elisaf MS. Current role of statins in the treatment of essential hypertension. Expert Opin Pharmacother 2010; 11: 2635-50.
221. Correa V Jr., Gus M, Fuchs FD. Does the blood pressure-lowering effect of statins contribute to their beneficial cardiovascular effects? Expert Rev Cardiovasc Ther 2010; 8: 775-9.
222. Juncos LI, Juncos LA, García NH. The antihypertensive actions of statins: modulation by salt intake. Am J Hypertens 2012; 25: 1140-8.
223. Drapala A, Sikora M, Ufnal M. Statins, the renin-angiotensinaldosterone system and hypertension-a tale of another beneficial effect of statins. J Renin Angiotensin Aldosterone Syst 2014; 15: 250-8.
224. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Statins and type 2 diabetes mellitus: an update after 1 year. Curr Pharm Des 2016; 22(18): 2723-5.
225. Katsiki N, Rizzo M, Mikhailidis DP, Mantzoros CS. New-onset diabetes andstatins: throw the bath water out, but, please, keep the baby! Metabolism 2015; 64(4): 471-5.
226. Athyros VG, Mikhailidis DP. Pharmacotherapy: statins and newonset diabetes mellitus--a matter for debate. Nat Rev Endocrinol 2012; 8: 133-4.
227. Banach M, Malodobra-Mazur M, Gluba A, Katsiki N, Rysz J, Dobrzyn A. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr Pharm Des 2013; 19: 4904-12.
228. Betteridge DJ, Carmena R. The diabetogenic action of statins-mechanisms and clinical implications. Nat Rev Endocrinol 2016; 12: 99-110.
229. Zafrir B, Jain M. Lipid-lowering therapies, glucose control and incidentdiabetes: evidence, mechanisms and clinical implications. Cardiovasc Drugs Ther 2014; 28: 361-77.
230. Dei Cas A, Fonarow GC, Gheorghiade M, Butler J. Concomitant diabetes mellitus and heart failure. Curr Probl Cardiol 2015; 40: 7-43.
231. Khan H, Kunutsor SK, Kauhanen J, et al. Fasting plasma glucose and incident heart failure risk: a population-based cohort study and new meta-analysis. J Card Fail 2014; 20: 584-92.
232. Varas-Lorenzo C, Margulis AV, Pladevall M, et al. The risk of heart failure associated withthe use of noninsulin blood glucoselowering drugs: systematic review andmeta-analysis of published observational studies. BMC Cardiovasc Disord 2014; 14: 129.
233. Gilbert RE, Krum H. Heart failure in diabetes: effects of antihyperglycaemic drug therapy. Lancet 2015; 385: 2107-17.
234. Tousoulis D, Oikonomou E, Siasos G, Stefanadis C. Statins in heartfailure--With preserved and reduced ejection fraction. An update. Pharmacol Ther 2014; 141: 79-91.
235. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004; 93: 1124-29.
236. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyörälä K. The eff ects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997; 3: 249-54.
237. Scirica BM, Morrow DA, Cannon CP, et al. for the PROVE ITTIMI 22 Investigators. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006; 47: 2326-31.
238. Khush KK, Waters DD, Bittner V, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007; 115: 576-83.
239. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307-16.
240. Kastelein JJP, van der Steeg WA, Holme I, et al. for the TNT and IDEAL Study Groups. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008; 117: 3002-09.
241. Scirica BM, Morrow DA, Cannon CP, et al. PROVE IT-TIMI 22 Investigators Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006; 47: 2326-31.
242. Dobre D, Rossignol P, Murin J, et al. Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trial. Eur J Heart Fail 2013; 15: 221-7.
243. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
244. Bonsu KO, Kadirvelu A, Reidpath DD. Statins in heart failure: do we need another trial? Vasc Health Risk Manag 2013; 9: 303-19.
245. Vrtovec B, Okrajsek R, Golicnik A, et al. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail 2008; 14: 140-4.
246. Wojnicz R, Wilczek K, Nowalany-Kozielska E, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 2006; 97: 899-904.
247. Xie RQ, Cui W, Liu F, Yang C, Pei WN, Lu JC. Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure. Int J Cardiol 2010; 140: 255-7.
248. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006; 47: 332-7.
249. Yamada T, Node K, Mine T, et al. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: A prospective randomized controlled study. Am Heart J 2007; 153: 1055. e1-1055. e8.
250. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idio¬pathic dilated cardiomyopathy. Circulation 2003; 108: 839-43.
251. Krum H, Ashton E, Reid C, et al. Double-Blind, randomized, placebo-controlled study of high-dose hmg coa reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007; 13: 1-7.
252. Hamaad A, Sosin M, Lip GY, MacFadyen RJ. Short-term adjuvant atorvastatin improves frequency domain indices of heart rate variability in stable systolic heart failure. Cardiovasc Drugs Ther 2005; 19: 183-7.
253. Bleske BE, Nicklas JM, Bard RL, et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 2006; 47: 338-41.
254. Wang JQ, Wu GR, Wang Z, Dai XP, Li XR. Long-term clinical outcomes of statin use for chronic heart failure: a meta-analysis of 15 prospective studies. Heart Lung Circ 2014; 23: 105-13.
255. Kjekshus J, Apetrei E, Barrios V, et al. CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-61.
256. Gissi-HF Investigators, Tavazzi L, Maggioni AP, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-9.
257. Preiss D, Campbell RT, Murray HM, et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J 2015; 36: 1536-46.
258. Liu G, Zheng XX, Xu YL, Lu J, Hui RT, Huang XH. Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials. Heart Lung Circ 2014; 23: 970-7.
259. Bonsu KO, Reidpath DD, Kadirvelu A. Effects of statin treatment on inflammation and cardiac function in heart failure: an adjusted indirect comparison meta-analysis of randomised trials. Cardiovasc Ther 2015; 33(6): 338-46.
260. Takano H, Mizuma H, Kuwabara Y, et al. PEARL Study Investigators. Effects of pitavastatin in Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study). Circ J 2013; 77: 917-25.
261. Liu G, Zheng XX, Xu YL, Ru J, Hui RT, Huang XH. Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction. Am J Cardiol 2014; 113: 1198-204.